Literature DB >> 3092728

Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.

K L Leenders, W H Poewe, A J Palmer, D P Brenton, R S Frackowiak.   

Abstract

The brain uptake of L-[18F]fluorodopa was measured by positron emission tomography in a healthy male volunteer both under fasting conditions and during intravenous amino acid loading. A significant reduction of tracer uptake into the brain was demonstrated with amino acid loading. This finding represents the first direct evidence for competition between L-dopa and other amino acids for uptake across the blood-brain barrier obtained in vivo in a human subject. It underlines the possible importance of interference by dietary amino acids with the therapeutic actions of L-dopa in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092728     DOI: 10.1002/ana.410200212

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.

Authors:  D R Robertson; I Higginson; B S Macklin; A G Renwick; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 2.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study.

Authors:  D Deleu; S Sarre; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

4.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients.

Authors:  K Ullrich; J Weglage; C Oberwittler; M Pietsch; B Fünders; H von Eckardstein; J P Colombo
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

6.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

7.  The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.

Authors:  J P Frankel; P A Kempster; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-09       Impact factor: 10.154

Review 8.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

9.  The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum.

Authors:  D Nilsson; U Fagerholm; H Lennernäs
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

10.  The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography.

Authors:  B J Snow; M Bhatt; W R Martin; D Li; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.